Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

CORRECTION: Direct by Syndicate Bio Launches to Power AI-Enabled Precision Medicine in Nigeria

  • AI-enabled genomic and multi-omics testing now available locally in Lagos through a new sequencing laboratory

  • Launch portfolio includes hereditary cancer and conditions panels, somatic oncology panels, NIPT, pharmacogenomics, and health & wellness testing

  • New Direct Nigeria Precision Medicine Network (DNPMN) to drive clinical adoption, with a joint tumor board in partnership with Roswell Park Comprehensive Cancer Center (USA)

Correction was made due to wrong image captions

LAGOS, NG / ACCESS Newswire / October 9, 2025 / Syndicate Bio today announced the launch of Direct by Syndicate Bio, a comprehensive genetic testing and precision medicine service designed to deliver actionable insights to patients, providers, and consumers across Africa. The launch coincides with the opening of a state-of-the-art sequencing laboratory in Lagos, enabling world-class genomic and multi-omics testing powered by AI-delivered locally for Nigeria's 200 million citizens and the global diaspora.

Syndicate Bio's Founder, Dr Abasi Ene-Obong, and the Syndicate Bio Nigeria team at the launch

Raising the Bar for Precision Medicine in Africa

The Lagos facility is built to set new global standards for precision medicine on the continent. Equipped with next-generation sequencing and advanced molecular workflows, the lab supports clinical-grade testing and research while ensuring faster turnaround times for Nigerian clinicians, researchers, and patients.

Nigeria's unparalleled ethnic diversity creates unique mutational signatures and drug-metabolism profiles. By integrating genomics, transcriptomics, and metabolomics with AI-driven analysis, Direct by Syndicate Bio will uncover biomarkers tailored to local populations-advancing precision medicine not only in Nigeria but also for millions worldwide who share genetic ancestry with its communities.

Launch Event and Stakeholder Engagement

The launch event, held at the new Lagos facility, brought together leading stakeholders, including representatives from the National Institute for Cancer Research and Treatment (NICRAT), Lakeshore Cancer Center, Redus Center for Digestive Health, Beacon Health, Healthtracka, Society for Family Health, and Atlantis Pediatric Hospital. Guests joined Syndicate Bio's Founder, Dr Abasi Ene-Obong, and the leadership team for a guided tour and introduction to the Direct platform.

Syndicate Bio's Founder, Dr Abasi Ene-Obong and Dr Usman Waziri, Director, Prevention and Control, NICRAT, during the tour of the state-of-the-art sequencing laboratory in Lagos

Dr Abasi Ene-Obong commented:

"Nigeria's diversity is both a challenge and an opportunity for precision medicine. For too long, the absence of locally derived genomic data has limited how we prevent, diagnose, and treat disease. With Direct, Syndicate Bio is harnessing Nigeria's rich genetic diversity to generate insights that improve care for Nigerians and the diaspora-while advancing inclusive precision medicine globally."

Comprehensive Testing Portfolio

Direct by Syndicate Bio launches with a focused portfolio addressing urgent healthcare needs:

  • Hereditary cancer testing: 300+ genes, including BRCA1/2 and others linked to breast, ovarian, pancreatic, prostate, and colorectal cancers

  • Hereditary conditions testing: 90 inherited disorders across cardiovascular, hematological, metabolic, neurodevelopmental, ophthalmological, and immune system categories

  • Health & Wellness testing: 80+ genes related to nutrition, metabolism, fitness, skin health, immunity, sleep, and lifestyle traits

  • Somatic oncology panels: Comprehensive solid and myeloid tumor profiling for targeted cancer treatment decisions

  • Non-invasive prenatal testing (NIPT): Early, safe assessment of fetal health

  • Pharmacogenomics: Drug selection and dosing guided by individual genetic profiles

  • Population-relevant traits: Sickle cell disease, thalassemia, G6PD deficiency, and hemophilia A/B included as standard

  • NGS-based testing: Next-generation sequencing ensures comprehensive results in the absence of large African genomic reference datasets

Reports are delivered in a clinician-ready format, supported by genetic counselling, with strict adherence to quality control, data protection, and privacy standards.

Driving Clinical Adoption: The Direct Nigeria Precision Medicine Network (DNPMN)

To accelerate adoption, Syndicate Bio has established the Direct Nigeria Precision Medicine Network (DNPMN) in partnership with leading institutions. The network will convene a multidisciplinary tumor board to enable local and international case collaboration, second opinions, and knowledge exchange.

Key partners include:

  • Lakeshore Cancer Center - Nigeria's premier oncology facility, providing advanced diagnostics, treatment and comprehensive patient support services

  • Redus Center for Digestive Health - leader in pancreatobiliary and digestive care, home to Nigeria's first endoscopic ultrasound program

  • Roswell Park Comprehensive Cancer Center (USA) - an NCI-designated Comprehensive Cancer Center, ranked among the top U.S. cancer centers

Through DNPMN, patients and at-risk families will gain access to personalized prevention and intervention strategies, including interventional endoscopies and risk-reducing surgeries, guided by genomic insights.

Syndicate Bio's Founder, Dr Abasi Ene-Obong, with Dr Usman Waziri, Director, Prevention and Control, NICRAT; Dr Onome Braimah, Head Medical Affairs, Syndicate Bio Nigeria; Dr Oge Ilegbune, Medical Director, Lakeshore Cancer Center; and other stakeholders at the launch.

Partner Perspectives

Dr Sai Yendamuri, Chief Strategy Officer, Roswell Park Comprehensive Cancer Center:

"We are honored to enter into this collaboration, which reflects our shared commitment to making precision medicine accessible to underserved populations across Africa. By combining our expertise in genomic testing with educational initiatives in oncology and cancer awareness, we can help empower clinicians and communities with the tools they need to improve outcomes. The creation of a joint tumor board will further strengthen this partnership, fostering multidisciplinary dialogue, advancing knowledge, and ensuring that patients benefit from the latest insights in genomics, personalized treatment, and clinical research."

Dr Chukwumere Nwogu, Co-Founder & CEO, Lakeshore Cancer Center:

"Partnering with Syndicate Bio allows us to offer precision oncology services that reflect the unique genetic profiles of our patients. This marks a milestone in bringing data-driven cancer care to Nigeria."

Dr Kenechukwu Chudy-Onwugaje, Founder & CEO, Redus Center for Digestive Health:

"Gastrointestinal cancer poses a growing public health challenge in Nigeria. Understanding genomic variation in digestive diseases ushers in a future where treatments are tailored to each patient's unique biology. Direct by Syndicate Bio equips clinicians with the tools to elevate care standards nationwide."

ENDS

For media enquiries or interview requests, please contact: Wimbart PR | syndicate.bio@wimbart.com

About Syndicate Bio

Syndicate Bio is Africa's leading health innovation platform, advancing genomics and precision medicine across the continent and beyond. Through partnerships with governments, pharmaceutical companies, and healthcare providers, Syndicate Bio develops scalable solutions tailored to Africa's unique health challenges. Guided by ethical governance and a commitment to patient empowerment, the company is shaping the future of precision medicine-from Africa to the world.

SOURCE: Direct by Syndicate Bio



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.